These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31433997)

  • 21. Results of Tobramycin Inhalation Therapy in Patients with Noncystic Fibrosis Bronchiectasis with
    Tanriverdi E; Yildirim BZ; Gul S; Chousein EGU; Turan D; Çınarka H; Özgül MA; Cetinkaya E
    J Aerosol Med Pulm Drug Deliv; 2021 Sep; 34(5):274-279. PubMed ID: 33351705
    [No Abstract]   [Full Text] [Related]  

  • 22. Dual antibiotics for bronchiectasis.
    Felix LM; Grundy S; Milan SJ; Armstrong R; Harrison H; Lynes D; Spencer S
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012514. PubMed ID: 29889304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
    Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
    Smith S; Rowbotham NJ; Charbek E
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD008319. PubMed ID: 30376155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sputum microbiota in adults with CF associates with response to inhaled tobramycin.
    Heirali A; Thornton C; Acosta N; Somayaji R; Laforest Lapointe I; Storey D; Rabin H; Waddell B; Rossi L; Arrieta MC; Surette M; Parkins MD
    Thorax; 2020 Dec; 75(12):1058-1064. PubMed ID: 33139451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis.
    Konstan MW; Flume PA; Galeva I; Wan R; Debonnett LM; Maykut RJ; Angyalosi G
    Pediatr Pulmonol; 2016 Apr; 51(4):372-8. PubMed ID: 26709158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
    Blasi F; Carnovale V; Cimino G; Lucidi V; Salvatore D; Messore B; Bartezaghi M; Muscianisi E; Porpiglia PA;
    Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis.
    Palser S; Smith S; Nash EF; Agarwal A; Smyth AR
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012300. PubMed ID: 31845758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.
    Sutharsan S; Naehrig S; Mellies U; Sieder C; Ziegler J
    BMC Pulm Med; 2020 Jun; 20(1):167. PubMed ID: 32532226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Case reports of the treatment with tobramycin solution for inhalation in severe bronchiectasis patients continuous infection of Pseudomonas aeruginosa].
    Nakamura S; Yanagihara K; Morinaga Y; Ohno H; Higashiyama Y; Miyazaki Y; Hirakata Y; Tashiro T; Kohno S
    Nihon Kokyuki Gakkai Zasshi; 2005 Jan; 43(1):41-7. PubMed ID: 15704452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis.
    Rubin BK
    J Aerosol Med Pulm Drug Deliv; 2008 Mar; 21(1):71-6. PubMed ID: 18518833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
    Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
    Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis.
    Barker AF; Couch L; Fiel SB; Gotfried MH; Ilowite J; Meyer KC; O'Donnell A; Sahn SA; Smith LJ; Stewart JO; Abuan T; Tully H; Van Dalfsen J; Wells CD; Quan J
    Am J Respir Crit Care Med; 2000 Aug; 162(2 Pt 1):481-5. PubMed ID: 10934074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
    Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
    J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
    Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B;
    Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
    Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
    Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.